Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03989466 · ClinicalTrials.gov registry record · Phase 1
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03989466: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03989466 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03989466, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with alemtuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving itacitinib and alemtuzumab may work better in treating patients with T-cell prolymphocytic leukemia compared to standard of care treatment.
Interventions
- DRUG Itacitinib
- BIOLOGICAL Alemtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2024-09-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03989466
The ClinicalTrials.gov registry entry for NCT03989466 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Itacitinib is the first listed.
NCT03989466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03989466 about?
NCT03989466 is a clinical study titled "Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia". This phase Ib trial studies the side effects and best dose of alemtuzumab when given together with itacitinib in treating patients with T-cell prolymphocytic leukemia. Itacitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with alemtuzuma...
What is the current status of trial NCT03989466?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2020-01-15. Estimated completion is 2024-09-24.
What interventions are being tested in trial NCT03989466?
The interventions under investigation include: Itacitinib (DRUG), Alemtuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03989466?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.